Makimoto Go, Kawakado Keita, Nakanishi Masamoto, Tamura Tomoki, Kuyama Shoichi
Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Case Rep Oncol. 2021 Mar 1;14(1):197-201. doi: 10.1159/000513624. eCollection 2021 Jan-Apr.
Alectinib is a key drug for treating ()-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of -positive adenocarcinoma successfully treated with lorlatinib after developing alectinib-induced hepatotoxicity. A 57-year-old Japanese man received alectinib as first-line therapy for -positive NSCLC. After 79 days, alectinib was discontinued because of hepatotoxicity and later restarted at 150 mg/day, inducing hepatotoxicity again after 64 days. Switching to lorlatinib treatment (continued for >4 months) caused no severe adverse effects. Hence, lorlatinib may be useful for patients experiencing alectinib-induced hepatotoxicity.
阿来替尼是治疗（）阳性非小细胞肺癌（NSCLC）的关键药物。与其他ALK抑制剂（如克唑替尼或色瑞替尼）相比，阿来替尼引起的肝毒性较少见。在此，我们描述了一例在发生阿来替尼诱导的肝毒性后成功用劳拉替尼治疗的（）阳性腺癌病例。一名57岁的日本男性接受阿来替尼作为（）阳性NSCLC的一线治疗。79天后，因肝毒性停用阿来替尼，之后以150mg/天的剂量重新开始使用，64天后再次引发肝毒性。改用劳拉替尼治疗（持续>4个月）未引起严重不良反应。因此，劳拉替尼可能对经历阿来替尼诱导肝毒性的患者有用。
